These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 8342796)
1. Should we use muscle biopsy to diagnose malignant hyperthermia susceptibility? Larach MG Anesthesiology; 1993 Jul; 79(1):1-4. PubMed ID: 8342796 [No Abstract] [Full Text] [Related]
2. Muscle biopsy for diagnosis of malignant hyperthermia susceptibility in two patients with severe exercise-induced myolysis. Hackl W; Winkler M; Mauritz W; Sporn P; Steinbereithner K Br J Anaesth; 1991 Jan; 66(1):138-40. PubMed ID: 1997050 [TBL] [Abstract][Full Text] [Related]
3. Muscle biopsy testing for malignant hyperthermia. Allen G; Rosenberg H Plast Reconstr Surg; 1989 Aug; 84(2):373-4. PubMed ID: 2748763 [No Abstract] [Full Text] [Related]
7. Propofol in malignant hyperthermia. Harrison GG Lancet; 1991 Feb; 337(8739):503. PubMed ID: 1671514 [No Abstract] [Full Text] [Related]
8. Diagnosis and management of susceptibility to malignant hyperthermia in pregnancy. Sorosky JI; Ingardia CJ; Botti JJ Am J Perinatol; 1989 Jan; 6(1):46-8. PubMed ID: 2910318 [TBL] [Abstract][Full Text] [Related]
9. [Prospective evaluation of a nuclear magnetic resonance score in the screening of malignant hyperthermia susceptibility. Initial results]. Payen JF; Bosson JL; Stieglitz P Ann Fr Anesth Reanim; 1996; 15(1):47-48. PubMed ID: 8729310 [TBL] [Abstract][Full Text] [Related]
10. Clinical concentrations of verapamil affect the in vitro diagnosis of susceptibility to malignant hyperpyrexia. Adnet PJ; Krivosic-Horber RM; Adamantidis MM; Haudecoeur G; Reyfort GH; Dupuis BA Br J Anaesth; 1990 Jan; 64(1):64-6. PubMed ID: 2302378 [TBL] [Abstract][Full Text] [Related]
11. Fatal reaction. Little S Nurs Times; 1990 Feb 28-Mar 6; 86(9):20-1. PubMed ID: 2315160 [No Abstract] [Full Text] [Related]
12. Clinical presentation of suspected malignant hyperthermia during anaesthesia in 402 probands. Ellis FR; Halsall PJ; Christian AS Anaesthesia; 1990 Oct; 45(10):838-41. PubMed ID: 2240497 [TBL] [Abstract][Full Text] [Related]
13. Malignant hyperthermia and central core disease: analysis of two families with heterogeneous clinical expression. Romero NB; Nivoche Y; Lunardi J; Bruneau B; Cheval MA; Hillaire D; Fardeau M Neuromuscul Disord; 1993; 3(5-6):547-51. PubMed ID: 8186709 [TBL] [Abstract][Full Text] [Related]
14. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Larach MG Anesth Analg; 1989 Oct; 69(4):511-5. PubMed ID: 2675676 [No Abstract] [Full Text] [Related]
15. General anesthesia with dexmedetomidine in a malignant hyperthermia-susceptible woman. Unger RJ Acta Anaesthesiol Scand; 2006 Nov; 50(10):1312-3. PubMed ID: 17067340 [No Abstract] [Full Text] [Related]
16. A medical student with malignant hyperthermia susceptibility. Underwood N; Austin JD Anaesth Intensive Care; 2012 Mar; 40(2):356. PubMed ID: 22417041 [No Abstract] [Full Text] [Related]